Repository logo
 
Publication

Dupilumab in Patients with Atopic Dermatitis: A Multicentric, Long-Term, Real-World Portuguese Study.

2024-08Text Open access
Simple item page
dc.contributor.authorTorres, Tiago
dc.contributor.authorCruz, Maria João
dc.contributor.authorGonçalo, Margarida
dc.contributor.authorFilipe, Paulo
dc.contributor.authorDuarte, Bruno
dc.contributor.authorAlves, João
dc.contributor.authorAlvarenga, José Miguel
dc.contributor.authorRosa, Gilberto
dc.contributor.authorFlor, Duarte
dc.contributor.authorRamos, José
dc.contributor.authorSousa, Diogo
dc.contributor.authorRosca, Aureliu
dc.contributor.authorMagalhães, César
dc.contributor.authorClaro, Cristina
dc.contributor.authorRocha, Joana
dc.contributor.authorVilarinho, Catarina
dc.contributor.authorMota, Fernando
dc.contributor.authorMota, Alberto
dc.contributor.authorLopes, Maria João Paiva
dc.date.accessioned2025-07-25T11:04:34Z
dc.date.available2025-07-25T11:04:34Z
dc.date.issued2024-08
dc.description.abstractIntroduction: Several clinical trials have established the efficacy and safety of dupilumab for treating atopic dermatitis (AD). However, literature remains scarce in reporting the long-term effectiveness, safety, and drug survival of dupilumab in real-world settings. This study aimed to describe the latter outcomes of dupilumab in patients with AD. Methods: This Portuguese, multicentric, observational, retrospective study included consecutive adult patients with AD who initiated dupilumab between January 2019 and September 2023, with a follow-up period up to 30 months. Drug discontinuation and adverse effects data were used to estimate drug survival. Clinical assessments included the Eczema Area and Severity Index (EASI), pruritus numerical rating scale (NRS), and Dermatology Life Quality Index (DLQI). Results: A total of 312 patients were included in the study, with 56.4% being male (median age of 30 years, range 18-83). The 30-month drug survival rate was 82.0%. During the study period, 12.5% of the sample (n = 39 patients) discontinued treatment: 7.3% due to treatment failure, 2.9% due to safety concerns, 1.3% due to complete disease control, 0.6% due to pregnancy, and 0.3% due to lack of compliance. Adverse events not leading to drug discontinuation were noted in 25.6% of the sample (n = 80). Conjunctivitis was the most frequently reported adverse event (17%), followed by facial erythema (9%). At 30 months, the mean EASI decreased significantly from 27.30 ± 11.89 at baseline to 2.92 ± 3.96 (p < 0.001), reflecting an overall improvement of 89.3%. Similarly, pruritus NRS decreased from 7.36 ± 1.90 at baseline to 1.74 ± 2.16 at month 30 (p < 0.001), improving by 76.4%, and mean DLQI changed from 18.0 ± 7.09 at baseline to 2.67 ± 3.95 at month 30 (p < 0.001), decreasing by 85.2%. Conclusions: This study increases our current understanding of dupilumab in real-world settings, demonstrating its long-term effectiveness and safety in treating AD.eng
dc.identifier.citationDermatol Ther (Heidelb) . 2024 Aug;14(8):2209-2221
dc.identifier.doi10.1007/s13555-024-01235-8
dc.identifier.other39039360
dc.identifier.urihttp://hdl.handle.net/10400.17/5120
dc.language.isoen
dc.peerreviewedyes
dc.publisherSpringerlink
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectAtopic dermatitis
dc.subjectDrug Survival
dc.subjectDupilumab
dc.subjectEffectiveness
dc.subjectLong-term
dc.titleDupilumab in Patients with Atopic Dermatitis: A Multicentric, Long-Term, Real-World Portuguese Study.
dc.typetext
dspace.entity.typePublication
oaire.citation.endPage2221
oaire.citation.issue8
oaire.citation.startPage2209
oaire.citation.volume14
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Dermatol Ther 2024_2209.pdf
Size:
667.83 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.03 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

DER - Artigos